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Abstract
Background: Robust reference values for fecal egg count reduction (FECR) rates of the most widely used anthelmintic drugs
in preventive chemotherapy (PC) programs for controlling soil-transmitted helminths (STHs; Ascaris lumbricoides, Trichuris
trichiura, and hookworm) are still lacking. However, they are urgently needed to ensure detection of reduced efficacies that
are predicted to occur due to growing drug pressure. Here, using a standardized methodology, we assessed the FECR rate
of a single oral dose of mebendazole (MEB; 500 mg) against STHs in six trials in school children in different locations around
the world. Our results are compared with those previously obtained for similarly conducted trials of a single oral dose of
albendazole (ALB; 400 mg).
Methodology: The efficacy of MEB, as assessed by FECR, was determined in six trials involving 5,830 school children in Brazil,
Cambodia, Cameroon, Ethiopia, United Republic of Tanzania, and Vietnam. The efficacy of MEB was compared to that of ALB
as previously assessed in 8,841 school children in India and all the above-mentioned study sites, using identical
methodologies.
Principal Findings: The estimated FECR rate [95% confidence interval] of MEB was highest for A. lumbricoides (97.6% [95.8;
99.5]), followed by hookworm (79.6% [71.0; 88.3]). For T. trichiura, the estimated FECR rate was 63.1% [51.6; 74.6]. Compared
to MEB, ALB was significantly more efficacious against hookworm (96.2% [91.1; 100], p,0.001) and only marginally,
although significantly, better against A. lumbricoides infections (99.9% [99.0; 100], p= 0.012), but equally efficacious for T.
trichiura infections (64.5% [44.4; 84.7], p= 0.906).
Conclusions/Significance: A minimum FECR rate of 95% for A. lumbricoides, 70% for hookworm, and 50% for T. trichiura is
expected in MEB-dependent PC programs. Lower FECR results may indicate the development of potential drug resistance.
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Introduction
The soil-transmitted helminths (STHs, Ascaris lumbricoides,
Trichuris trichiura, and the two hookworm species, Necator
americanus and Ancylostoma duodenale) are responsible for the
highest burden among all neglected tropical diseases (NTDs) [1].
Recent global estimates indicate that in 2010 more than 1.4 billion
people were infected with at least one of the four STH species,
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resulting in a global burden of approximately 5.2 million disability-
adjusted life years (DALYs) (20% of the total number of DALYs
attributable to NTDs) [2]. Mass drug administration (MDA)
programmes in which a single oral dose of albendazole (ALB) or
mebendazole (MEB) - the drugs of choice for STHs - are
periodically administered to pre-school and school aged children,
are the main strategy for controlling the morbidity caused by STH
[3,4], and these programmes have recently received increased
political and scientific attention [5,6].
While the laudable long-term aim is to eliminate soil-transmit-
ted helminthiasis as public problem by 2020 [7], the pledges of
drug donations on this scale re-enforce the necessity for thoroughly
designed monitoring systems that allow detection of any changes
in anthelmintic drug efficacy that may arise through the evolution
of anthelmintic drug resistance in these parasites. Both ALB and
MEB belong to the same pharmaceutical group (benzimidazole
drugs, BZ) sharing the same mode of action (the inhibition of the
polymerisation of microtubules). Thus, development of resistance
against any BZ drug would most likely by accompanied by poor
anthelmintic drug efficacy of the other BZ drugs. It is pertinent
also that there is a paucity of anthelmintic drugs licensed for the
treatment of STH infections in humans and available commer-
cially, and hence should anthelmintic resistance against BZ drugs
eventually emerge and spread, chemotherapy based control of
STHs will be even more limited than at present with few
acceptable alternative options [8].
Currently, assessment of the reduction in fecal egg counts
following drug administration (fecal egg count reduction (FECR)
syn. egg reduction rate) is the recommended method for
monitoring the efficacy of anthelmintic drugs against STHs [9].
In contrast to other available assays, it allows for the assessment of
drug efficacy against all three STHs (vs. in vitro assays and
molecular assays) with a minimum of laboratory equipment (vs.
molecular assays) [10–12]. However, the interpretation of the
results from the FECR tests remains difficult, since reliable
reference efficacy values for BZ drugs (which can act as standard
reference points for comparison with new data) for each of the
STH species are still lacking. In a systematic review and meta-
analysis of published efficacy trials targeting STH infections,
Keiser and Utzinger (2008) [13] highlighted that there is a lack of
high-quality trials to determine these reference values. The
available efficacy data have been obtained through a variety of
widely differing study protocols, including protocols that used
different diagnostic methods, different durations in follow-up
periods, differing origin of the drugs (i.e., different manufactures
and therefore different quality), and statistical analyses, all of
which impede a robust meta-analysis of drug efficacy based on
FECR [13]. As a response to these earlier limitations, our
consortium has recently reported on the efficacy of a single oral
dose of ALB (400 mg) against STH in seven trials across sub-
Saharan Africa, Asia, and Latin America based on a protocol
standardized in respect to the origin of the drug (Zentel,
GlaxoSmithKline, batch Nu L298), the follow-up period (14 to
30 days), the egg counting method (McMaster egg counting
method), the statistical analysis, and the interpretation of the data
(group based FECR using arithmetic means) [14]. This study
suggested that a FECR of 95% for A. lumbricoides and 90% for
hookworm should be the expected minimum in all future drug
efficacy studies, and that FECR rates below these levels following a
single dose of ALB, should be viewed as danger signs of potential
development of drug resistance. For T. trichiura, reference FECR
values could only be provided for specified mean fecal egg count
(FEC) values at pre-intervention, as the drug efficacy measured by
FECR decreased as a function of increasing mean FEC at the pre-
intervention survey. For T. trichiura, we therefore expect FECRs
of at least 90%, 70%, and 50%, in populations where the mean
FECs are below 275 eggs per 1 g of stool (EPG), 550 EPG, and
800 EPG, respectively, and even lower in settings where baseline
infection intensities are higher [15]. Data derived from such
standardized multi-center efficacy trials that establish reliable
reference FECR values and assess the impact of infection intensity
are still currently lacking for MEB. Therefore, in the present study
we assessed the efficacy measured by means of FECR of a single
oral dose of MEB (500 mg) against STHs in six trials in sub-
Saharan Africa, Asia, and Latin America using a protocol that we
previously standardized in assessing the drug efficacy of a single
dose of ALB, and compared the drug efficacy of both BZ drugs
against each of the STHs.
Methods
Ethics statement
The overall protocol of both the ALB and MEB trials was
approved by the Ethics Committee of the Faculty of Medicine,
Ghent University (reference nos. B67020084254 and 2011/374)
and was followed by local ethical approval for each trial site. For
Brazil, approval was obtained from the Institutional Review Board
from Centro de Pesquisas Rene´ Rachou (no. 21/2008), for
Cambodia from the National Ethics Committee for Health
Research (no. 185 NECHR), for Cameroon from the National
Ethics Committee (nos. 072/CNE/DNM08, 147/CNE/DNM/
11), for India from the Institutional Review Board of the Christian
Medical College (Vellore) (no. 6541; participated in the ALB study
only), for Ethiopia from the Ethical Review Board of Jimma
University (Jimma) (no. RPGE/09/2011), for United Republic of
Tanzania from the Zanzibar Health Research Council (nos. 20,
ZAMREC/0003/JUNE/2012), and for Vietnam by Ethical
Committee of National Institute of Malariology, Parasitology
and Entomology (Ha Noi) and the Ministry of Health (no. 752/
QD-VSR). The parents of all subjects included in the studies
Author Summary
Soil-transmitted helminths (STHs; roundworms, whip-
worms, and hookworms) infect millions of children in
sub-tropical and tropical countries, resulting in malnutri-
tion, growth stunting, intellectual retardation, and cogni-
tive deficits. To fight against STH, large-scale deworming
programs are implemented in which anthelmintic drugs
(either albendazole (ALB) or mebendazole (MEB)) are
administered. Currently, these large-scale programs are
intensifying, highlighting the need to closely monitor the
efficacy of anthelmintic drugs to detect changes in drug
efficacy that may arise through the evolution of anthel-
mintic drug resistance in the parasites. We have previously
defined the minimum expected efficacy of ALB based on
the fecal egg count reduction (FECR) rate, but these
reference values are lacking for MEB. Therefore, we
therefore evaluated the FECR rate of MEB against STHs in
six STH endemic countries. In addition, we compared the
results of the FECR rate for MEB with those we obtained
previously for ALB. The results confirm that MEB treatment
was highly efficacious against roundworms, and to a lesser
extend against hookworms, but not against whipworms.
Compared to ALB, MEB is less efficacious against hook-
worm, but equally efficacious against roundworms and
whipworms. Based on this study we propose the minimum
expected FECR rate for MEB-dependent large-scale de-
worming programs.
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signed an informed consent form. In Brazil and Ethiopia an
informed consent form was obtained from children aged 10 or 11
years and above. In Cambodia and Ethiopia, a verbal assent was
obtained from all children, and this procedure was approved by the
respective ethics boards. Our studies assessing ALB and MEB are
registered under ClinicalTrials.gov, identifiers nos. NCT01087099
and NCT01379326, respectively (CONSORT Checklist S1).
Trial Sites
The MEB multi-center study reported here was carried out in
six countries located in sub-Saharan Africa (Cameroon, Ethiopia,
and United Republic of Tanzania (Zanzibar)), Asia (Cambodia
and Vietnam), and Latin America (Brazil). However, it is
important to note that, while we refer to individual countries to
identify results from particular trials, names of countries are used
Figure 1. Study participation, occurrence of soil-transmitted helminth infections, and stool sample submission compliance during
the mebendazole-intervention. These surveys were conducted in six soil-transmitted helminth-endemic countries (i.e. Brazil, Cambodia,
Cameroon, Ethiopia, United Republic of Tanzania, and Vietnam) between December 2011 and April 2012. Subjects who were not able to provide a
stool sample for the follow-up, or who were experiencing a severe intercurrent medical condition or had diarrhea at the time of the first sampling,
were excluded from the trial.
doi:10.1371/journal.pntd.0003204.g001
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only to distinguish between six separate trials that were conducted
in six geographically distinct regions of the world. These six STH-
endemic countries were selected because of the presence of
investigator groups/institutions with extensive experience in the
diagnosis, and control of STH. These same six investigator groups
were also involved in the earlier evaluation of the efficacy of a
single-oral dose 400 mg ALB against STH in children, based on
an identical standardized protocol [14].
Trial Design and Field Work
Since study designs can have a significant effect on the
subsequent calculation of efficacy and to ensure that our values
for ALB and MEB were not confounded by study design, the
protocol described by Vercruysse and colleagues for assessment of
ALB was also used here to evaluate the drug efficacy of MEB [14].
In short, schools were selected based on previous STH surveys.
Within schools, children were recruited on a voluntary basis.
School children aged 4–18 years at each of the different trial sites
were asked to provide a stool sample during a pre-intervention
survey. For the initial sampling the aim was to enroll at least 250
STH-infected children for at least one species. This sample size
was selected based on statistical analysis of study power, using
random simulations of correlated over-dispersed FEC data
reflecting the variance-covariance structure in a selection of real
FEC data sets. This analysis suggested that a sample size of up to
200 individuals (alpha = 0.05, power = 80%) was required to detect
a 10% point drop from a null efficacy of 80% (mean FECR
individual) over a wide range of infection scenarios. Standard
power analyses for proportions also indicated that the detection of
a 10% point drop from a null cure rate required sample sizes up to
200 (the largest samples being required to detect departures from
null efficacies of around 50%). Given an anticipated non-
compliance rate of 25%, a total of at least 250 individuals was
therefore considered necessary at each study site. A single oral
dose of 500 mg MEB (Vermox) from the same manufacturer
(Janssen-Cilag, Latina, Italy, batch no: BCL2F00) was adminis-
tered to the subjects at all study sites. Seven to 15 days after the
pre-intervention survey (Brazil: 7–14 days; Cambodia: 11–15 days;
Cameroon: 9–11 days; Ethiopia: 14 days; United Republic of
Tanzania: 14 days; Vietnam: 11–12 days), stool samples were
again collected from the subjects. Subjects who were unable to
provide a stool sample at follow-up, or who were experiencing a
severe intercurrent medical condition or had diarrhea at the time
Figure 2. Efficacy of a single dose of mebendazole against soil-transmitted helminths. Three forest plots summarizing the anthelmintic
drug efficacy measured by means of fecal egg reduction (FECR) rate of a single oral dose of 500 mg mebendazole against Ascaris lumbricoides,
Trichuris trichiura, and hookworm infections, respectively.
doi:10.1371/journal.pntd.0003204.g002
Figure 3. Comparison of efficacy between a single dose of albendazole and mebendazole against Ascaris lumbricoides infections.
Forest plot comparing the anthelmintic drug efficacy measured by means of fecal egg reduction (FECR) rate of a single oral dose of 400 mg
albendazole (ALB) and a single oral dose of 500 mg mebendazole (MEB) against A. lumbricoides infection.
doi:10.1371/journal.pntd.0003204.g003
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of the first sampling, were excluded from the study (Study Protocol
S1).
Laboratory Procedures
All stool samples were individually processed by the McMaster
egg counting method. McMaster is a flotation technique that is
commonly used in veterinary parasitology both to assess intensity
of gastro-intestinal parasite infections and to evaluate drug efficacy
against these parasites. For the diagnosis and enumeration of
STHs in public health, it has been found to be user-friendly (vs.
FLOTAC [16]) robust (vs. Kato-Katz thick smear [17]) and
accurate for enumeration of STHs, but less sensitive when
intensity of infection is low (vs. Kato-Katz and FLOTAC
[16,17])) Complementary data indicate that FECR estimates
obtained by the McMaster are comparable to those using the
Kato-Katz thick smear [18,19].
The standard operating procedure to perform a McMaster on
human stools is described in more detail elsewhere [15]. Briefly,
2 g of stool were suspended in 30 ml of saturated salt (NaCl)
solution at room temperature (density: 1.2). The fecal suspension
was poured three times through a tea sieve to remove large debris.
After thorough mixing 10 times, 0.5 ml aliquots were added to
each side of a McMaster slide chamber. Both chambers were
examined under a light microscope using 100x magnification and
the FEC, expressed as EPG for each helminth species, was
obtained by multiplying the total number of eggs counted under
the microscope by a factor 50. A detailed tutorial can be found on
http://www.youtube.com/watch?v=UZ8tzswA3tc.
Statistical Analysis
The efficacy of a single dose of MEB (500 mg) against each of
the three STH species (the two hookworm species were treated as
one species since the eggs of A. duodenale and N. americanus
cannot be distinguished by conventional microscopy), as measured
by FECR, was calculated for the different trials. We have not
summarized the efficacy of MEB by means of cure rate (CR; the
proportion of the subjects who are not excreting eggs after drug
administration). This is because an intervention may fail to cure
STH infections (CR=0%), but may result in a FECR of 99%,
which is satisfactory. Second, it has been shown that estimates of
CR are highly affected by both sampling and diagnostic effort,
estimates being overestimated when the sampling and diagnostic
effort is minimized. This was in sharp contrast to FECR estimates,
which remained unchanged regardless of both sampling and
diagnostic effort [20].
To-date, a wide range of formulae has been used to calculate
FECR, each differing in terms of the statistical unit (individual vs.
group) and how the mean FEC is calculated (arithmetic vs.
geometric). However, recent studies suggest that the group-based
formula using the arithmetic mean, as described below, is a
suitable metric for evaluating drug efficacy. Compared to the other
formulae, it represents a robust indicator (vs. individual-based
formula [14]) that provides accurate estimates of drug efficacy (vs.
group-based formula using geometric mean) [14,21]. Moreover, it
is important to note that there is no common formula for
calculating the variance for each of these FECR formulae. The
formula used here to calculate variance for the group-based FECR
Figure 4. Comparison of efficacy between a single dose of albendazole and mebendazole against Trichuris trichiura infection. Forest
plot comparing the anthelmintic drug efficacy measured by means of fecal egg reduction (FECR) rate of a single oral dose of 400 mg albendazole
(ALB) and a single oral dose of 500 mg mebendazole (MEB) against T. trichiura infection.
doi:10.1371/journal.pntd.0003204.g004
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using the arithmetic mean is described below and is based on the
Delta method [22].
FECR(%)~100%x 1-
AR mean post-FECð Þ
AR mean pre-FECð Þ
 
var FECR %½ ð Þ~10,000x AR mean post-FECð Þ
AR mean pre-FECð Þ
 2
x
var pre-FECð Þ
AR mean pre-FECð Þ2z
var post-FECð Þ
AR mean post-FECð Þ2 -
2xcor pre-FEC, post-FECð Þx ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffivar pre-FECð Þxvar post-FECð Þp
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FECR~fecal egg count reduction
AR~arithmetic
pre-FEC~individual fecal egg count at pre-intervention
post-FEC~individual fecal egg count post-intervention
var~variance
cor~Pearson0s correlation coefficient
We first analyzed the trial outcomes for each of the three STHs
separately using FECR data at the trial level, and its correspond-
ing variance and sample size, and secondly we compared data
from both the current trials with MEB and our earlier trials with
ALB, employing meta-analytical approaches. In addition, the
impact of infection intensity at the pre-intervention survey on the
FECR rate of both BZ drugs was evaluated. To assess the FECR
rate of MEB, generalized mixed effect models were fitted for each
of the three STH species in turn, with the FECR rate at the trial
level as the dependent variable, and the mean FEC at the pre-
intervention survey as a covariate. To compare the FECR rates
between ALB and MEB, generalized mixed effect models were
fitted for each of the three STH species with FECR at the trial
level as the dependent variable, and BZ drug (two levels: ALB and
MEB) and mean FEC at the pre-intervention survey as covariates,
and the interaction between these covariates. For both analyses,
we only included trials for which at least 50 subjects who had been
treated and provided stools at both pre- and post-intervention
surveys were available. The different MEB and ALB trials
included in the analyses are listed in Table 1 and Table 2,
respectively. These tables also describe for each trial the sample
size, mean age, sex ratio (number of female subjects/number of
male subjects), mean FEC, and the level of infection intensity at
the pre-intervention survey for each of the three STH species
Figure 5. Comparison of efficacy between a single dose of albendazole and mebendazole against hookworm infection. Forest plot
comparing the anthelmintic drug efficacy measured by means of fecal egg reduction (FECR) rate of a single oral dose of 400 mg albendazole (ALB)
and a single oral dose of 500 mg mebendazole (MEB) against hookworm infections.
doi:10.1371/journal.pntd.0003204.g005
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separately. The levels of infection intensity correspond to the low,
moderate, and high intensity of infection ranges, as described by
WHO [23]. For A. lumbricoides these were 1–4,999 EPG, 5,000–
49,999 EPG, and $50,000 EPG; for T. trichiura these levels were
1–999 EPG, 1,000–9,999 EPG, and $10,000 EPG; and for
hookworm these were 1–1,999 EPG, 2,000–3,999 EPG, and $
4,000 EPG, respectively. The ALB trials have been described
previously by Vercruysse et al. (2011) [14] and Mekonnen et al.
(2013) [24], targeting A. lumbricoides (five trials), T. trichiura (five
trials), and hookworm (7 trials). Each of these trials report FECR
rates of a single dose ALB (400 mg), all were based on the
aforementioned trial design, and with the exception of one trial
(India) the same laboratories which assessed the FECR rates in
current study were also involved in these ALB trials. The meta-
analysis was carried out using the ‘metafor’ package of the statistical
software R [25]. The level of significance was set at p,0.05.
Results
The numbers of subjects enrolled for the study, allocated to the
intervention, receiving treatment, and then providing samples at
both pre- and post-intervention surveys are summarized in
Figure 1. For infections with each species of STH we also provide
the number of subjects who were included in the statistical
analysis. Trials in which fewer than 50 subjects carried a specific
parasite were not included in the statistical analysis.
FECR for MEB
Figure 2 illustrates the outcome of the analyses of FECR of
MEB by means of forest plots for A. lumbricoides, T. trichiura, and
hookworm infections. Overall, the estimated FECR rate [95%
confidence interval [CI]] of MEB was the highest for A.
lumbricoides (97.6% [95.8–99.5]), followed by hookworm (79.6%
[71.0–88.3]). For T. trichiura, the estimated FECR rate was lower,
namely 63.1% [51.6–74.6]. An association between the mean
FECs at pre-intervention and the FECR rate was observed for A.
lumbricoides only. For this STH species, the model predicted that
the FECR rate would drop by 0.4% as mean FECs at pre-
intervention increase by increments of 1,000 EPG (z = -2.97,
p=0.003). For the remaining two STHs, there was no significant
relationship between FECR rate and mean FEC at pre-
intervention (T. trichiura: z = 1.46, p=0.144; hookworm:
z = 1.00, p=0.316).
Comparison of FECR between ALB and MEB
Figures 3 to 5 illustrate the outcome of the meta-analyses of the
FECR rate against STHs for ALB and MEB by means of forest
plots for A. lumbricoides, T. trichiura, and hookworm infections,
Figure 6. The efficacy albendazole and mebendazole, as a function of infection intensity at the pre-treatment survey. The estimated
efficacy measured by means of fecal egg reduction (FECR) rate (straight line) and 95% confidence intervals (dashed line) of a single oral dose of
400 mg ALB (black) and a single dose of 500 mg MEB (red) as a function of infection intensity at the pre-treatment survey (means of FEC) for Ascaris
lumbricoides, and Trichuris trichiura.
doi:10.1371/journal.pntd.0003204.g006
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respectively. Overall, ALB resulted in statistically higher FECR
rates against A. lumbricoides (ALB: 99.9% [99.0–100] vs. MEB:
98.0% [96.9–99.1], z =22.5, p=0.012) and hookworm infections
(ALB: 96.2% [91.1–100] vs. MEB: 80.6% [74.4–86.8], z = 37.4,
p,0.001). For T. trichiura there was no significant difference in
FECR rate (ALB: 64.5% [44.4–84.7] vs. MEB: 62.7% [40.8–
84.6], z =20.1, p=0.906).
Associations between mean FEC at pre-intervention and the
FECR rate were observed for both A. lumbricoides and T.
trichiura but in respect of different AE, (Figure 6). For A.
lumbricoides, the model predicted that the FECR rate after
treatment with ALB should remain unchanged across mean FEC
at pre-intervention, but that the FECR rate after MEB treatment
should fall on average by 0.4% for each 1,000 EPG incremental
increase in mean FEC at pre-intervention (interaction term
between BZ drug and mean FEC at the pre-intervention survey,
z =22.93, p=0.033). For T. trichiura, the model predicted that
the FECR rate following treatment with ALB should decrease on
average by 7.8% per incremental increase of 100 EPG in mean
FEC at pre-intervention ( = main effect of mean FEC at the pre-
intervention, z =29.1, p,0.001). However, there was a significant
interaction between BZ drug and mean FEC at pre-intervention
(z = 6.9, p,0.001), indicating a significant difference between the
two BZ drugs in the rate of fall of the FECR rate with increasing
pre-intervention FEC. In contrast to the 7.8% fall/100 EPG
increment for ALB, for MEB, the model predicted a net fall in
FECR rate of only 1.1%/100 EPG increment, which as shown
earlier when assessed separately from ALB, did not represent a
significant association. For hookworm, the FECR rate of both BZ
drugs did not depend significantly on the mean FEC at pre-
intervention.
Discussion
This is the first study that has generated a robust, reliable
estimation of the FECR rate following treatment with MEB, and
has compared thoroughly the efficacy of MEB with that of ALB,
against STH infections. Although we must acknowledge some
variation in follow-up period across the trials, both the ALB and
MEB trials were standardized at a level unprecedented in the
scientific literature [14]. Moreover, most previous studies evalu-
ating drug efficacy of BZ drugs against STHs have generally not
summarized their efficacy results by means of the group-based
FECR formula, using the arithmetic mean and its corresponding
95% CI, which are now recognized as a suitable, indeed the most
informative metric, for the outcome of such trials [14] and are
needed to enable a meta-analysis of drug efficacy against STHs
[13,14].
Overall, the results of this study indicate that a single oral dose
of MEB is most efficacious against A. lumbricoides infections,
followed by hookworm, but that it is relatively inefficacious for
infections with T. trichiura, thus confirming the earlier efficacy
studies reviewed by Bennett and Guyatt [26] and Keiser and
Utzinger [13]. The relatively poor efficacy of a single dose
treatment with either MEB or ALB in reducing T. trichiura FECs
is not a novel finding [13,26], and has resulted in ongoing research
on the development and evaluation of new drugs or drug
combinations that reduce T. trichiura worm burdens more
effectively following single dose application, e.g. pyrantel/oxantel
[27], mebendazole/ivermectine [28], oxantel, [29], and papaya
cysteine proteinases [30]. Based on the overall drug efficacy results
for the three STH species, we recommend that monitoring
programs of single-dose MEB-dependent PC use a minimum
FECR (group-based formula using arithmetic mean) of 95% for A.
lumbricoides, 70% for hookworm, and 50% for T. trichiura as
appropriate reference values (as they are below the lower limit of
the 95% CI of overall estimates), and that efficacy levels below this
should raise concern about the possible emergence of drug
resistance.
Compared to a single oral dose of ALB, MEB was significantly
less efficacious against hookworm and to a lesser extent against A.
lumbricoides infections, but equally inefficacious for T. trichiura
infection. In addition, the efficacies of both ALB and MEB were
dependent on the intensity of A. lumbricoides and T. trichiura
infection, decreasing with increasing infection intensity. However,
the magnitude of this loss of efficacy as a function of increasing
infection intensity differed between the two BZ drugs and the STH
species. Between the BZ drugs, the change in drug efficacy was
more pronounced for MEB with A. lumbricoides, whereas for T.
trichiura the decrease was more pronounced for ALB. Among
STHs, the overall impact of infection intensity on treatment
with BZ was pronounced for T. trichiura (1.2–7.8% per 100
EPG), but almost negligible for A. lumbricoides (0.4% per 1,000
EPG). For hookworm, the efficacy did not depend on the
infection intensity. This could be explained by either a true
constant efficacy across infection intensities or a low number of
moderate and high infection intensities in these trials (see
Table 1). The bases of these differences in efficacy between the
BZ drugs and their effects on STHs remain unclear, mainly due
to the paucity of detailed pharmacokinetic and pharmacody-
namics studies in pediatric populations in STH-endemic
countries [31].
Currently, recommendations in PC programs are solely
based on the overall prevalence of STHs, with these drugs
being administered once a year when the STH prevalence is $
20% and ,50%, and twice a year when the prevalence is $
50% [4]. Although this study indicates that the best choice of
BZ drug depends on the relative prevalence and species of
STH infections (ALB: hookworm. T. trichiura; MEB: T.
trichiura. hookworm), practical experience with both drugs in
the field over several years indicates that both are equally
effective in controlling all three STH species irrespective of
their initial prevalence and intensity of infection [32,33].
However, future studies are required to (i) evaluate the
difference between BZ drugs in long-term impact (prevalence,
infection intensity, and occurrence of single nucleotide poly-
morphisms in the b-tubulin gene associated with BZ resis-
tance); (ii) determine STH-specific thresholds for infection
intensity to justify choice of BZ drugs; and (iii) assess the cost-
effectiveness of distributing more than one class of BZ to
different regions in a country [12,34].
In conclusion, our findings suggest that FECR rates exceeding
95% for A. lumbricoides, 70% for hookworm, and 50% for T.
trichiura should be expected in all future surveys, and that any
FECR rate below these levels following a single oral dose of MEB
(500 mg) should be viewed with concern in light of potential
development of drug resistance. In addition, the study highlights
the need for detailed pharmacokinetic/pharmacodynamic studies
for single-oral dose of BZ drugs in pediatric populations in
countries where STHs are endemic to gain additional insights into
the observed differences in drug efficacy between ALB and MEB
across the various STH species. Finally, additional recommenda-
tions advising those running PC programs about which of the BZ
drugs to administer in a given setting (i.e., depending on the extent
of T. trichiura and hookworm infections in a specific location/
population) may improve the long-term benefits accruing from PC
programs.
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